scholarly journals The Economic Effect of Screening Orthopedic Surgery Patients Preoperatively for Methicillin-Resistant Staphylococcus aureus

2010 ◽  
Vol 31 (11) ◽  
pp. 1130-1138 ◽  
Author(s):  
Bruce Y. Lee ◽  
Ann E. Wiringa ◽  
Rachel R. Bailey ◽  
Vishal Goyal ◽  
Becky Tsui ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Orthopedic Surgery ◽  
Economic Value ◽  
Third Party ◽  
Computer Simulation Model ◽  
Preoperative Screening ◽  
Methicillin Resistant ◽  
Party Payer ◽  
The Third ◽  
The Third Party

Background and Objective.Patients undergoing orthopedic surgery are susceptible to methicillin-resistant Staphylococcus aureus (MRSA) infections, which can result in increased morbidity, hospital lengths of stay, and medical costs. We sought to estimate the economic value of routine preoperative MRSA screening and decolonization of orthopedic surgery patients.Methods.A stochastic decision-analytic computer simulation model was used to evaluate the economic value of implementing this strategy (compared with no preoperative screening or decolonization) among orthopedic surgery patients from both the third-party payer and hospital perspectives. Sensitivity analyses explored the effects of varying MRSA colonization prevalence, the cost of screening and decolonization, and the probability of decolonization success.Results.Preoperative MRSA screening and decolonization was strongly cost-effective (incremental cost-effectiveness ratio less than $6,000 per quality-adjusted life year) from the third-party payer perspective even when MRSA prevalence was as low as 1%, decolonization success was as low as 25%, and decolonization costs were as high as $300 per patient. In most scenarios this strategy was economically dominant (ie, less costly and more effective than no screening). From the hospital perspective, preoperative MRSA screening and decolonization was the economically dominant strategy for all scenarios explored.Conclusions.Routine preoperative screening and decolonization of orthopedic surgery patients may under many circumstances save hospitals and third-party payers money while providing health benefits.

scholarly journals Should Vascular Surgery Patients Be Screened Preoperatively for Methicillin-Resistant Staphylococcus aureus?

2009 ◽  
Vol 30 (12) ◽  
pp. 1158-1165 ◽  
Author(s):  
Bruce Y. Lee ◽  
Becky Y. Tsui ◽  
Rachel R. Bailey ◽  
Kenneth J. Smith ◽  
Robert R. Muder ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Vascular Surgery ◽  
Success Rate ◽  
Economic Value ◽  
Cost Effective ◽  
Third Party ◽  
Computer Simulation Model ◽  
Success Rates ◽  
Methicillin Resistant ◽  
Wide Range

Background.Methicillin-resistant Staphylococcus aureus (MRSA) can cause severe infection in patients who are undergoing vascular surgical operations. Testing all vascular surgery patients preoperatively for MRSA and attempting to decolonize those who have positive results may be a strategy to prevent MRSA infection. The economic value of such a strategy has not yet been determined.Methods.We developed a decision-analytic computer simulation model to determine the economic value of using such a strategy before all vascular surgical procedures from the societal and third-party payer perspectives at different MRSA prevalence and decolonization success rates.Results.The model showed preoperative MRSA testing to be cost-effective (incremental cost-effectiveness ratio, <$50,000 per quality-adjusted life year) when the MRSA prevalence is ≥0.01 and the decolonization success rate is ≥0.25. In fact, this strategy was dominant (ie, less costly and more effective) at the following thresholds: MRSA prevalence ≥0.01 and decolonization success rate ≥0.5, and MRSA prevalence ≥0.025 and decolonization success rate ≥0.25.Conclusion.Testing and decolonizing patients for MRSA before vascular surgery may be a cost-effective strategy over a wide range of MRSA prevalence and decolonization success rates.

scholarly journals AB0810 COST-EFFECTIVENESS ANALYSIS OF THE CLINICAL APPROACH FOR RA PATIENTS IN THE EARLY PHASE VERSUS THOSE IN THE ESTABLISHED PHASE FROM A FOURTH-LEVEL HEALTH SERVICE PROVIDER INSTITUTION IN COLOMBIA

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1429.2-1429
Author(s):  
C. Sarmiento Peña ◽  
G. Quintana Lopez ◽  
J. A. Díaz
Keyword(s):  
Rheumatoid Arthritis ◽  
Cost Effectiveness ◽  
Early Phase ◽  
Third Party ◽  
Clinical Approach ◽  
Health Service Provider ◽  
Party Payer ◽  
The Third ◽  
Fourth Level ◽  
The Third Party

Background:Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that without treatment causes disability, pain, quality of life impairment, and premature mortality. It causes significant economic repercussions on patients, their families, and the health system. The costs of RA for Sanitary Systems are described in terms of medications and hospitalization. Also, the cost of treatment for patients whose disease was not adequately controlled from an early stage may involve joint replacement surgery and prolonged hospitalizations.Objectives:To determine and analyze the cost-effectiveness of the clinical approach to rheumatoid arthritis in a cohort of patients in the early phase versus a cohort of patients in the established phase from a fourth-level Health Service Provider Institution in Colombia, from the perspective of the third-party payer with a time horizon of six-months.Methods:An economic evaluation of the cost-effectiveness of the clinical approach was carried out in the early phase versus the established phase in a cohort of patients from May 2013 until December 2018, with rheumatoid arthritis from a fourth-level Health Service Provider Institution in Colombia, from the perspective of the third-party payer with a time horizon of six-months. The costs and effectiveness of each of the phases were estimated. A decision tree model was created, and the incremental cost-effectiveness ratio was calculated. The deterministic and probabilistic sensitivity analysis was performed.Results:The early phase clinical approach for patients with rheumatoid arthritis represents savings of approximately 600 USD per patient in remission or low disease activity level in the first 6 months of follow-up from the perspective of the third-party payer.Conclusion:The clinical approach to rheumatoid arthritis in the early phase is a less costly and more effective alternative versus established phase and generates savings for the third-party payer with a time horizon of six-months.Figure 1.Acceptability curveDisclosure of Interests:None declared

scholarly journals Execution rights model on trademark as guarantee object to credit bank

2020 ◽  
Vol 9 (4) ◽  
pp. e199942755
Author(s):  
Trisadini Prasastinah Usanti
Keyword(s):  
Economic Value ◽  
Third Party ◽  
Director General ◽  
Legal Certainty ◽  
The Third ◽  
The Third Party

Based on requirement that must to fulfill that the object is able to be a object guarantee so Trademark Rights is qualify the requirement as object guarantee because have economic value and able to transferred with written agreement. In Juridical, existence of trademark rights is guarantee legal certainty for repayment of debtor debt or implementation of an achievement although in practice banking trademark rights only as additional guarantee. Guarantee institution that possible to burden it is mortgage or fiduciary guarantee. In this article this is focusing on fiduciary guarantee. When the debtor wanprestasie so the trademark rights as fiduciary object guarantee allow doing execution either by parate execution, executorial title or by selling privately made agreement. However, creditor or debtor is able to make an effort by finding buyers who are willing to buy the trademark rights. Whenever a buyer is found and serve so a deed of transfer is made on trademark in authentic then it follows with removal of fiduciary guarantee and recording of transfer of trademark rights that registered to Director General IPR until transfer of trademark rights besides giving legal certainty for buyer and also binding the third party.

scholarly journals Investing in public health from the perspective of the third party payer – NFZ (NFH)

2013 ◽  
Vol 11 (41) ◽  
pp. 204-226
Author(s):  
Jadwiga Suchecka ◽  
Zofia Skrzypczak
Keyword(s):  
Public Health ◽  
Third Party ◽  
Party Payer ◽  
The Third ◽  
The Third Party

scholarly journals Does the Identity of the Third-Party Payer Matter for Prescribing Doctors?

2014 ◽  
Vol 1 (1) ◽  
Author(s):  
Dag Morten Dalen ◽  
Marilena Locatelli ◽  
Enrico Sorisio ◽  
Steinar Strøm
Keyword(s):  
Third Party ◽  
Party Payer ◽  
The Third ◽  
The Third Party
Sign in / Sign up

Export Citation Format

Share Document